Molecular characterization and follow‐up of five CML patients with new BCR–ABL1 fusion transcripts

E-ISSN： 1098-2264|54|10|595-605

ISSN： 1045-2257

Source： GENES, CHROMOSOMES AND CANCER, Vol.54, Iss.10, 2015-10, pp. : 595-605

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute Lymphoblastic Leukaemia with an e1a3 BCR-ABL1 Fusion

Acta Haematologica, Vol. 126, Iss. 4, 2011-09 ,pp. : 214-215

Karger

Access to resources Recommend Favorite

Comparison of FISH and Quantitative RT-PCR for the Diagnosis and Follow-Up of BCR-ABL -Positive Leukemias

By Bao Fei

Molecular Diagnosis & Therapy, Vol. 11, Iss. 4, 2007-01 ,pp. : 239-245

Adis International

Access to resources Recommend Favorite

Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of the BCR-ABL Fusion Gene in Natural Killer Cells in Patients with Chronic Myelogenous Leukemia

Acta Haematologica, Vol. 104, Iss. 2-3, 2001-01 ,pp. : 135-138

Karger

Access to resources Recommend Favorite